Esketamine-Led Opioid-Free Anaesthesia Lowers PPCs in Bariatric Surgery
Key Takeaways
- Postoperative pulmonary complications were lower with the esketamine-led approach than with opioid-balanced anesthesia.
- Opioid use during the first 24 postoperative hours was lower, while pain scores stayed similar and the reduction remained below the stated 10 MME threshold.
- Hypoxemia was less frequent, whereas nystagmus occurred only with esketamine-led anaesthesia and PACU stay was longer.
This prospective randomized controlled trial enrolled patients scheduled for laparoscopic bariatric surgery under combined intravenous-inhalation anesthesia in a defined perioperative pathway. Investigators screened 263 patients and enrolled 100, creating a randomized cohort for perioperative comparison.
Participants were assigned either to the esketamine-led opioid-free S-Ket group or to the SR-Fen group using sufentanil and remifentanil. Postoperative pulmonary complication incidence was the primary outcome, while secondary measures included total morphine milligram equivalents and visual analogue scale pain scores. The trial focused on pulmonary events and early recovery measures within the same operative setting and postoperative observation window.
Among the specific pulmonary findings, hypoxemia showed the clearest between-group difference after surgery. Hypoxemia occurred in 22.0% of S-Ket patients and 42.0% of SR-Fen patients, with RR 0.52, 95% CI 0.28-0.97, and P=0.032. Opioid consumption during the first 24 postoperative hours was significantly lower with S-Ket, with P=0.025. Visual analogue scale pain scores were comparable between groups at all reported postoperative time points, and the opioid reduction did not reach 10 MME. Together, these findings showed lower early opioid exposure without a measurable difference in reported postoperative pain intensity across the recorded time points.
Nystagmus appeared only in the S-Ket group, affecting 56.0% of patients versus none in SR-Fen, with P<0.001. PACU stay was also longer in S-Ket, with P=0.039 for that difference. No other significant between-group safety differences were reported in the available summary of postoperative adverse events and recovery findings.
Overall, the randomized comparison published on 06 May 2026 paired fewer pulmonary complications with mixed recovery and safety observations in this bariatric cohort.
Frequently Asked Questions
What are best practices for anesthesia in obese patients?
Anesthesia for obese patients undergoing laparoscopic bariatric surgery emphasizes lung-protective ventilation, careful airway management, opioid-sparing approaches to reduce postoperative pulmonary complications, and short-acting agents to enable early extubation. In this randomized trial, an esketamine-led opioid-free strategy (S-Ket) reduced postoperative pulmonary complications versus sufentanil-remifentanil opioid-balanced anesthesia (SR-Fen) — 26.0% vs 50.0%, RR 0.52 (95% CI 0.30-0.89), P=0.013 — and reduced hypoxemia (22.0% vs 42.0%; RR 0.52, 95% CI 0.28-0.97; P=0.032). Pain control at standardized postoperative timepoints was similar between groups, and 24-hour opioid consumption was lower with S-Ket (P=0.025; absolute reduction below 10 MME). Trade-offs included transient nystagmus (56.0% S-Ket vs 0%) and longer PACU stay.
What's new in bariatric and metabolic surgery?
Beyond ongoing refinement of laparoscopic and metabolic procedures (sleeve gastrectomy, Roux-en-Y gastric bypass, single-anastomosis techniques) and integration with obesity pharmacotherapy, perioperative anesthesia care is evolving toward opioid-sparing strategies. This randomized comparison published 06 May 2026 in BMC Anesthesiology adds evidence that esketamine-led opioid-free anesthesia can lower postoperative pulmonary complications in laparoscopic bariatric surgery. The result reinforces the broader enhanced-recovery-after-surgery (ERAS) movement toward multimodal analgesia and opioid reduction, with attention to drug-class-specific side effects (here, transient nystagmus and longer PACU stay with esketamine).
Where can I find CME on perioperative GLP-1 management?
Although this trial tested esketamine, the same patient population — adults undergoing bariatric or metabolic surgery — increasingly presents on chronic GLP-1 receptor agonist therapy for obesity or type 2 diabetes, raising distinct perioperative concerns (delayed gastric emptying, aspiration risk on induction). CME on perioperative GLP-1 management is at Anesthesiology — Clinical Practice and Surgery CME. Both are free after a no-cost ReachMD registration. Anesthesia teams should coordinate preoperative GLP-1 holding decisions, fasting interval, and induction technique per current society guidance, separately from any intraoperative analgesic strategy chosen.
What were the safety and recovery trade-offs of esketamine-led anesthesia in this trial?
The esketamine-led arm had higher rates of two protocol-specific findings: nystagmus, which occurred in 56.0% of S-Ket patients versus 0% in SR-Fen (P<0.001), and longer PACU stay (P=0.039 for the between-group difference). Nystagmus is a known transient ketamine/esketamine effect. The 24-hour postoperative opioid reduction was statistically significant (P=0.025) but did not exceed 10 morphine milligram equivalents, and pain scores were comparable between groups at all reported postoperative timepoints. No other significant between-group safety differences were reported in the available summary.
How generalizable are these findings and what design caveats apply?
The trial enrolled 100 of 263 screened patients in a single-protocol perioperative pathway for laparoscopic bariatric surgery under combined intravenous-inhalation anesthesia. The available summary does not specify the country of origin, surgeon and anesthetist experience, or specific bariatric procedures performed. Generalization to other bariatric surgery populations, surgical approaches, or anesthesia teams should be made cautiously. The trial was not blinded, the sample is modest, and the primary endpoint (postoperative pulmonary complications) is a composite that may be defined differently across institutions. Replication in larger, multicenter cohorts with standardized PPC definitions would strengthen the evidence base.